Physician profile
Rebecca D Brauner
NPI 1871526970
$40,354.42
in general payments reported to CMS, 2019-2025
21 companies · $7,826 in 2025
The $7,826 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,145 · 2022: $7,161 · 2023: $2,001 · 2024: $16K · 2025: $7,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,999 · Travel and Lodging: $2,574 · Consulting Fee: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Food and Beverage | $5,998.80 |
| Travel and Lodging | $2,574.13 |
| Consulting Fee | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34,016.35 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $1,612.80 | 2022-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $852.52 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $693.02 | 2021-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.37 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $351.56 | 2023-2025 | Capvaxive, Winrevair |
| Inari Medical, INC. | $283.38 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $269.45 | 2022-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $241.56 | 2023-2025 | |
| Mylan Specialty L.P. | $155.23 | 2022-2023 | |
| Insmed, INC. | $136.59 | 2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $135.40 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.13 | 2023 | Glassia |
| Jazz Pharmaceuticals INC. | $117.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $112.14 | 2023 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $111.31 | 2024 | Remodulin, Tyvaso |
| Pfizer INC. | $111.26 | 2025 | |
| Abbvie INC. | $104.77 | 2021 | |
| Mallinckrodt Hospital Products INC. | $87.79 | 2022 | |
| Philips North America LLC | $73.05 | 2022 | |
| Grifols Shared Services North America, INC. | $71.94 | 2023 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Brauner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.